Info

Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Of its six programs in development, four are in late stage: its telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas Pharma Inc. (Astellas), its Horizon program (formerly referred to as Beyond Advair) with GlaxoSmithKline plc (GSK), its Gastrointestinal Motility Dysfunction program, and TD-1792, its investigational antibiotic for the treatment of serious Gram-positive bacterial infections.(Source: 10-K)